TITLE:
The Impact of Chemotherapy on EGFR Mutation Status in Non-Small-Cell Lung Cancer: A Meta-Analysis
AUTHORS:
Xiaoshun Shi, Fuxi Huang, Allen M. Chen, Zhuolin Wu, Qianqian Huang, Ying Liang, Qipeng Zhou, Haiyun Mo, Xiaoxiang Li, Jiexia Zhang
KEYWORDS:
EGFR Mutation, Chemotherapy, Non-Small Cell Lung Cancer, Me-ta-Analysis
JOURNAL NAME:
Open Journal of Genetics,
Vol.7 No.4,
December
21,
2017
ABSTRACT: Background: Emerging evidence indicates that chemotherapy for lung cancer may alter
EGFR mutation status. However, whether chemotherapy as a firstline treatment
may increase or reduce the frequency of EGFR mutations in NSCLC remains
uncertain. Therefore, we conducted a meta-analysis to evaluate whether
chemotherapy leads to altered EGFR mutation status. Methods: A
systematic literature search was performed using the PubMed, OVID, Science Direct,
Cochrane Library, and CNKI databases for studies on pre- and post-chemotherapy EGFR mutation status. Relevant
studies documenting perichemotherapy EGFR mutation ratios were
included. Analyses of pooled odds ratios (OR) were performed. Results: Six studies involving 656 patients were included in this meta-analysis. It was
found that chemotherapy may alter EGFR status (OR = 1.93, 95% CI 1.05 - 3.56; p
Conclusions: Chemotherapy may contribute to
altered EGFR status. NSCLC patients with EGFR mutations might need to be
considered for EGFR status redeterminations prior to second-line EGFR-TKI
treatment or upon tumor recurrence after chemotherapy. Further randomized
clinical trials should investigate the impact of neoadjuvant or first-line
chemotherapy on EGFR mutation status in NSCLC patients.